SOURCE: Skystar Bio-Pharmaceutical Company

January 09, 2007 09:30 ET

Skystar Bio-Pharmaceutical Signs Letter of Intent for Joint Scientific Research Project

XI'AN, CHINA -- (MARKET WIRE) -- January 9, 2007 -- Skystar Bio-Pharmaceutical (OTCBB: SKBI), a leading bio-pharmaceutical company in China, today announced that it has signed a letter of intent to initiate a joint scientific research project with Dr. Nicholas P. Plotnikoff, Chairman and CEO of TNI-Penta.

Dr. Plotnikoff and his team met with Skystar Bio-Pharmaceutical executive management and top research team in Xi'an, China recently to discuss the joint project and conduct academic surveys. The joint project will include research in the areas of development of Avian Flu Vaccine, Cancer, AIDS Vaccine and Treatment, the application of biotechnology in animal husbandry, and the application of newly developed technology by Dr. Plotnikoff to enhance existing and/or new health drugs and bio-products for human therapeutics.

Weibing Lu, Chairman and CEO of Skystar Bio-Pharmaceutical, commented, "We are very pleased to be working closely with Dr. Plotnikoff and his team and very excited at the possibility of using both our resources to potentially discover new products that will serve to improve the way of life for millions of people around the world."

Nicholas P. Plotnikoff, Ph.D., is Chairman and CEO of TNI-Penta (a joint venture between TNI Pharmaceuticals and Pentabiotech). In addition, Dr. Plotnikoff is a professor of Pharmacology at the College of Pharmacy, University of Illinois/Chicago, as well as the College of Medicine and the Graduate College. His principal research interests are in the areas of psychoneuroimmunology with special emphasis on stress hormones and cytokines (enkephalins-endorphins). His current research has been focused on the clinical effects of methionine enkaphalin in the treatment of cancer and AIDS patients. He also cooperated with Hualan Chen, who is Chief Leader of Animal Influza Key Opening Lab of Harbin Veterinary Research Institute of Chinese Academic of Agricultural Sciences, council member of avian diseases branch of Chinese Association of Animal Science and Veterinary Medicine, in the research of Avian Flu Vaccine. Dr. Plotnikoff was also a senior member of the 1977 Nobel Prize-winning team in medicine.

If you would like to be added to Skystar Bio-Pharmaceutical's investor email list please contact Zack Noory with Nexus Investor Relations at

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 70 state-of-the-art products with over 50 additional products in the developmental stage. One of the prominent products currently in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed strategic sales distribution networks in 27 provinces and regions throughout China. Skystar recently completed construction of new state-of-the-art Bio-Pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit

Forward-looking statement: Except for the historical information, the matters discussed in this news release may contain forward-looking statements, including, but not limited to, factors relating to future sales. These forward-looking statements may involve a number of risks and uncertainties. Actual results may vary significantly based on a number of factors, including, but not limited to, uncertainties in product demand, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors detailed in the company's most recent annual report and other filings with the Securities and Exchange Commission.

Contact Information

    Scott Cramer
    Director - Investor Relations
    Email Contact

    Zack Noory
    Managing Partner
    Email Contact